Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Is photodynamic therapy ready to move beyond facial use in actinic keratosis care? Biofrontera Inc.’s Phase 3 Ameluz data extend photodynamic therapy beyond the face. Find out how this could reshape field treatment decisions. bySoujanya RaviFebruary 13, 2026